health
Semaglutide lowered heart-filling pressures in obesity-related HFpEF trial
In a 52-week placebo-controlled trial of 81 people with obesity and HFpEF, semaglutide lowered pulmonary artery wedge pressure at rest and during exercise. More than half of participants assigned semaglutide met the study’s definition of hemodynamic remission.